Headlines about Exact Sciences Corporation (NASDAQ:EXAS) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exact Sciences Corporation earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.5203402262522 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Technical check on Exact Sciences Corporation (EXAS) – Stocks Gallery (stocksgallery.com)
- Exact Sciences Corporation (NASDAQ: EXAS) – Technicals in Focus – Alpha Beta Stock (alphabetastock.com)
- Today’s Research Reports on Trending Tickers: Exact Sciences and Gilead Sciences (finance.yahoo.com)
- Exact Sciences to Expand Laboratory and Corporate Facilities in Madison (finance.yahoo.com)
- Head to Head Review: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS) (americanbankingnews.com)
A number of equities research analysts have recently issued reports on EXAS shares. BTIG Research reaffirmed a “buy” rating and set a $45.00 target price (up from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Canaccord Genuity reiterated a “buy” rating and set a $42.00 price target (up previously from $38.00) on shares of Exact Sciences Corporation in a report on Thursday, July 20th. Vetr upgraded Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 price target on the stock in a report on Tuesday, July 25th. Lake Street Capital lifted their price target on Exact Sciences Corporation from $30.00 to $41.00 and gave the company a “hold” rating in a report on Wednesday, July 26th. Finally, Craig Hallum restated a “buy” rating and issued a $46.00 target price (up previously from $41.00) on shares of Exact Sciences Corporation in a research note on Wednesday, July 26th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Exact Sciences Corporation has an average rating of “Buy” and a consensus target price of $49.71.
Shares of Exact Sciences Corporation (EXAS) traded up $1.19 on Friday, reaching $60.37. The company’s stock had a trading volume of 1,352,200 shares, compared to its average volume of 2,562,707. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $63.60.
Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The company had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.36) EPS. analysts forecast that Exact Sciences Corporation will post -1.14 EPS for the current year.
In other Exact Sciences Corporation news, insider Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $40.81, for a total value of $3,088,623.23. Following the sale, the insider now owns 308,377 shares of the company’s stock, valued at approximately $12,584,865.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas D. Carey purchased 2,500 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was purchased at an average cost of $37.71 per share, for a total transaction of $94,275.00. Following the purchase, the director now directly owns 60,858 shares in the company, valued at $2,294,955.18. The disclosure for this purchase can be found here. Insiders have sold a total of 277,373 shares of company stock worth $12,635,570 in the last ninety days. 4.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://stocknewstimes.com/2017/11/11/exact-sciences-corporation-exas-getting-somewhat-positive-media-coverage-analysis-finds.html.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.